Literature DB >> 23063097

Mutations in the gyrA and parC genes of quinolone-resistant Neisseria gonorrhoeae isolates in India.

Sangeeta Kulkarni1, Manju Bala, Suvarna Sane, Sudhanshu Pandey, Jayanta Bhattacharya, Arun Risbud.   

Abstract

A dramatic increase in the number of quinolone-resistant Neisseria gonorrhoeae isolates in India and worldwide has been reported recently. This study was undertaken to identify and characterise mutations in the gyrA and parC genes of N. gonorrhoeae resistant to six different quinolone antibiotics. In total, 64 N. gonorrhoeae clinical isolates were obtained during 2007-2009 from patients attending sexually transmitted diseases clinics (New Delhi, 35; Pune, 16; Mumbai, 6; Hyderabad, 6; and Nagpur, 1). Antimicrobial susceptibility was determined by Etest and mutation patterns in gyrA and parC were determined by sequencing analysis. All strains showed varying resistance to different quinolone analogues, ranging from 17.2% (gatifloxacin) to 98.4% (ofloxacin and norfloxacin). Sequencing of gyrA and parC revealed that 100% of strains showed mutations in gyrA and 46.9% showed mutations both in gyrA and parC. All strains showed single or double mutations at Ser-91→Phe, Ser-91→Thr and Asp-95→Gly/Asn in gyrA and at Glu-91→Gly in parC. Asp-95→Asn mutation was the most prevalent in strains isolated from New Delhi, whilst Asp-95→Gly was prevalent in strains isolated from Pune. Strains were categorised into eight different mutation patterns. Resistant strains with high minimum inhibitory concentrations (≥8 μg/mL) showed mutations both in gyrA and parC. The difference in the proportion of strains showing mutations in gyrA and parC was found to be significant (P<0.001). The mutation Asp-95→Asn was restricted to Pune strains only. These results indicate that mutations in quinolone target enzymes may have resulted in the high-level resistance seen in these isolates.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23063097     DOI: 10.1016/j.ijantimicag.2012.08.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  Codon 91 Gyrase A Testing Is Necessary and Sufficient to Predict Ciprofloxacin Susceptibility in Neisseria gonorrhoeae.

Authors:  Lao-Tzu Allan-Blitz; Jeffrey D Klausner
Journal:  J Infect Dis       Date:  2017-02-01       Impact factor: 5.226

2.  Exploring quinolone resistance-determining region in Neisseria gonorrhoeae isolates from across India.

Authors:  Seema Sood; Madhav Agarwal; Manju Bala; Neeraj Mahajan; Rajendra Singh; Arti Kapil; Vishnubhatla Sreenivas; R J Ram; Hemanta Kumar Kar; Vinod Kumar Sharma
Journal:  Indian J Med Res       Date:  2017-07       Impact factor: 2.375

3.  Genomic surveillance of Neisseria gonorrhoeae to investigate the distribution and evolution of antimicrobial-resistance determinants and lineages.

Authors:  Koji Yahara; Shu-Ichi Nakayama; Ken Shimuta; Ken-Ichi Lee; Masatomo Morita; Takuya Kawahata; Toshiro Kuroki; Yuko Watanabe; Hitomi Ohya; Mitsuru Yasuda; Takashi Deguchi; Xavier Didelot; Makoto Ohnishi
Journal:  Microb Genom       Date:  2018-07-31

Review 4.  Multiresistant Neisseria gonorrhoeae: a new threat in second decade of the XXI century.

Authors:  Beata Młynarczyk-Bonikowska; Anna Majewska; Magdalena Malejczyk; Grażyna Młynarczyk; Sławomir Majewski
Journal:  Med Microbiol Immunol       Date:  2019-12-04       Impact factor: 3.402

5.  Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from India, Pakistan and Bhutan in 2007-2011.

Authors:  Sunil Sethi; Daniel Golparian; Manju Bala; Dorji Dorji; Muhammad Ibrahim; Kausar Jabeen; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2013-01-24       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.